Marvelon/Marvelon 28

Marvelon/Marvelon 28

desogestrel + ethinylestradiol




Zuellig Pharma
Concise Prescribing Info
Desogestrel 0.15 mg, ethinylestradiol 0.03 mg, 7 placebo tab (Marvelon 28 only)
Dosage/Direction for Use
1 tab daily starting on 1st day of menstruation followed by 7 tab-free days (Marvelon 21 only). May be started on days 2-5 of cycle but w/ additional contraceptive method (barrier method) for first 7 days of administration in the 1st cycle.
May be taken with or without food.
Hypersensitivity. History of thrombosis or embolus; heart attack (eg, angina pectoris or chest pain) or stroke (eg, transient ischaemic attack or small reversible stroke); blood clotting disturbance (eg, protein C deficiency); major surgery, limited movements for a long period of time; migraine w/ aura; DM w/ blood vessel damage; risk factors for thrombosis; pancreatitis; jaundice or severe liver disease; cancer that may grow under influence of sex hormones (eg, breast or genital organs); liver tumour; unexplained vag bleeding; liver tumour. Patients w/ hepatitis C & taking combination drug regimen ombitasvir/paritaprevir/ritonavir w/ or w/o dasabuvir. Pregnancy.
Special Precautions
Smoking (especially women >35 yr); diabetes; overwt; high BP; heart valve or certain heart rhythm disorder; inflammation of veins (superficial phlebitis); varicose veins; thrombosis, heart attack or stroke; migraine; epilepsy; high cholesterol or triglycerides; breast cancer; liver or gallbladder disease; Crohn's disease or ulcerative colitis (chronic inflammatory bowel disease); SLE; haemolytic uraemic syndrome; sickle cell disease; operation or limited movements for a long period of time; increased risk of blood clots in patients who recently gave birth; condition that occurred for the 1st time or worsened during pregnancy or previous use of sex hormones (eg, hearing loss, porphyria, herpes gestationis, Sydenham's chorea); chloasma (avoid excessive sun or UV light exposure). High risk of thrombosis especially in patients who restart treatment after a ≥4 wk interruption of therapy. Discontinue treatment if signs of thrombosis occur. Risk of breast cancer. Concomitant use w/ primidone, phenytoin, phenobarb, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, ritonavir, nelfinavir, nevirapine, efavirenz, boceprevir, telaprevir, griseofulvin, bosentan, St. John's wort; ciclosporin, lamotrigine; combination drug regimen ombitasvir/paritaprevir/ritonavir w/ or w/o dasabuvir. May affect any blood or urinary test. Patients w/ hepatitis C. Intolerance to some sugars. Pregnancy & lactation.
Adverse Reactions
Depressed mood, mood changes; headache; nausea, abdominal pain; breast pain & tenderness; increased body wt.
Drug Interactions
Reduced efficacy w/ primidone, phenytoin, phenobarb, carbamazepine, oxcarbazepine, topiramate, felbamate; rifampicin; ritonavir, nelfinavir, nevirapine, efavirenz; boceprevir, telaprevir; griseofulvin; bosentan; St. John's wort. May increase effect of cyclosporine. May decrease effect of lamotrigine. May increase liver function blood test results w/ combination drug regimen ombitasvir/paritaprevir/ritonavir, w/ or w/o dasabuvir.
MIMS Class
ATC Classification
G03AA09 - desogestrel and ethinylestradiol ; Belongs to the class of progestogens and estrogens in fixed combinations. Used as systemic contraceptives.
Marvelon 28 tab
Marvelon tab
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in